116 related articles for article (PubMed ID: 28119123)
1. A novel injectable formulation of 6-fluoro-l-DOPA imaging agent for diagnosis of neuroendocrine tumors and Parkinson's disease.
Trapani A; Tricarico D; Mele A; Maqoud F; Mandracchia D; Vitale P; Capriati V; Trapani G; Dimiccoli V; Tolomeo A; Scilimati A
Int J Pharm; 2017 Mar; 519(1-2):304-313. PubMed ID: 28119123
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical development of novel lactate-based 6-fluoro-l-DOPA formulations.
Denora N; Lopedota A; de Candia M; Cellamare S; Degennaro L; Luisi R; Mele A; Tricarico D; Cutrignelli A; Laquintana V; Altomare CD; Franco M; Dimiccoli V; Tolomeo A; Scilimati A
Eur J Pharm Sci; 2017 Mar; 99():361-368. PubMed ID: 27717874
[TBL] [Abstract][Full Text] [Related]
3. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution.
Kuik WJ; Kema IP; Brouwers AH; Zijlma R; Neumann KD; Dierckx RA; DiMagno SG; Elsinga PH
J Nucl Med; 2015 Jan; 56(1):106-12. PubMed ID: 25500826
[TBL] [Abstract][Full Text] [Related]
4. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
5. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles.
Di Gioia S; Trapani A; Mandracchia D; De Giglio E; Cometa S; Mangini V; Arnesano F; Belgiovine G; Castellani S; Pace L; Lavecchia MA; Trapani G; Conese M; Puglisi G; Cassano T
Eur J Pharm Biopharm; 2015 Aug; 94():180-93. PubMed ID: 26032293
[TBL] [Abstract][Full Text] [Related]
7. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.
Kauhanen S; Seppänen M; Minn H; Gullichsen R; Salonen A; Alanen K; Parkkola R; Solin O; Bergman J; Sane T; Salmi J; Välimäki M; Nuutila P
J Clin Endocrinol Metab; 2007 Apr; 92(4):1237-44. PubMed ID: 17227804
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
9. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
Lopci E; Piccardo A; Nanni C; Altrinetti V; Garaventa A; Pession A; Cistaro A; Chiti A; Villavecchia G; Fanti S
Clin Nucl Med; 2012 Apr; 37(4):e73-8. PubMed ID: 22391727
[TBL] [Abstract][Full Text] [Related]
10. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
11. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
[TBL] [Abstract][Full Text] [Related]
12. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
14. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
15. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children.
Ribeiro MJ; Boddaert N; Bellanné-Chantelot C; Bourgeois S; Valayannopoulos V; Delzescaux T; Jaubert F; Nihoul-Fékété C; Brunelle F; De Lonlay P
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2120-8. PubMed ID: 17661030
[TBL] [Abstract][Full Text] [Related]
16. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
17. Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.
Picco A; Morbelli S; Piccardo A; Arnaldi D; Girtler N; Brugnolo A; Bossert I; Marinelli L; Castaldi A; De Carli F; Campus C; Abbruzzese G; Nobili F
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1062-70. PubMed ID: 25820675
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of endocrine neoplasms with emphasis on 18F-DOPA PET: a practical approach for well-tailored imaging protocols.
Fargette C; Imperiale A; Taïeb D
Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):141-147. PubMed ID: 35343670
[TBL] [Abstract][Full Text] [Related]
19. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.
Calabria FF; Calabria E; Gangemi V; Cascini GL
Hell J Nucl Med; 2016; 19(1):33-41. PubMed ID: 26929938
[TBL] [Abstract][Full Text] [Related]
20. Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.
Morana G; Piccardo A; Milanaccio C; Puntoni M; Nozza P; Cama A; Zefiro D; Cabria M; Rossi A; Garrè ML
J Nucl Med; 2014 May; 55(5):718-23. PubMed ID: 24652828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
